Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH
Bremen, HB
- UEI
- FEKLLV3GP6R4
- CAGE
- CF058
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- International Organization
- SAM.gov registration date
- Physical address
- Achterstraße 30, 28359 Bremen, Germany
- Website
- bips-institut.de
- Founded
- 1981
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Etiologic heterogeneity between molecular subtypes of prostate cancer | National Cancer Institute (NIH) | $3,967,540 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Johns Hopkins University | R01CA300353 | $62,367 | |
| The Johns Hopkins University | HT94252510665 | $92,664 |
Similar vendors
About the company
Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH, a German non-profit research institute headquartered in Bremen, operates as a federal grant recipient focused on cancer epidemiology and molecular subtyping research, with a footprint split between one prime grant and two sub-grants from the National Institutes of Health and the Defense Health Agency.
The organization holds a single prime federal grant award from the National Cancer Institute (NIH): a five-year project grant (Aug 1, 2023 to Jul 31, 2028) investigating etiologic heterogeneity between molecular subtypes of prostate cancer. The work involves molecular profiling of 3,373 prostate tumors from 107,313 men across three prospective cohort studies (the Health Professionals Follow-Up Study, the Physicians' Health Study, and the Southern Community Cohort Study), with an emphasis on applying in-situ pathology methods to identify gene fusions, tumor suppressor loss, and oncogene gain across distinct molecular phenotypes. The project aims to identify risk factors specific to molecular subtypes and lay groundwork for primary prevention efforts.
As a sub-recipient, Leibniz-Institut appears on two Johns Hopkins University-led grants within the same domain. The institute provides co-leadership of the Prostate Cancer Cohort Consortium (PC3) and leads data harmonization across cohorts on a sub-award dated Sep 8, 2026. A second Johns Hopkins sub-award dated Jan 26, 2026 addresses AI and digital pathology applications for predicting lethal outcomes in population-based prostate cancer cohorts (PC24041).
Federal customer concentration is narrow. The National Cancer Institute accounts for two of three awards, with the Defense Health Agency representing the third. Combined dollars obligated across all awards total $4.1 million. Activity is sparse — one award in 2023, two in 2026 — with one award (the prime NCI grant) facing ultimate completion on Jul 31, 2028, outside the next twenty-four-month recompete window.
Quick answers
Is Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH registered in SAM.gov?
Yes. Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH's SAM.gov registration is active through June 30, 2027.
What is Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH's most recent federal award?
Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH's most recent federal grant award is Etiologic heterogeneity between molecular subtypes of prostate cancer (R37CA275914), from National Cancer Institute (NIH), on August 1, 2023.
On GovTribe
See Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors